Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GTXi (GTXI) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (22)	12/7/2006 8:35:12 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 85

GTx Announces Conference Call and Webcast to Discuss Ostarine Phase II Clinical Trial Results and an Update on GTx SARM Program Thursday December 7, 4:54 pm ET MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI - News), the Men's Health Biotech Company, announced that it will host a conference call and webcast tomorrow, December 8, 2006, at 9:00 a.m. Eastern Time to discuss results of the ostarine Phase II proof of concept clinical trial and to provide an update on its SARM program. GTx will issue a press release announcing the clinical trial results and SARM program update before the call. To listen to the conference call, please dial: 866-202-4367 from the United States and Canada or 617-213-8845 (International) The access code for the call is 32056343. A playback of the call will be available beginning tomorrow at 11:00 a.m. Eastern Time through December 22, and may be accessed by dialing: 888-286-8010 from the United States and Canada or 617-801-6888 (International) The reservation number for the replay is 89704161.

To: keokalani'nui who wrote (22)	12/13/2006 7:26:12 PM
From: keokalani'nui	Respond to of 85

GTx Announces Registered Direct Common Stock Offering of $60.8 Million Wednesday December 13, 4:04 pm ET MEMPHIS, Tenn., Dec. 13 /PRNewswire-FirstCall/ -- GTx, Inc. (Nasdaq: GTXI - News), the Men's Health Biotech Company, announced today that it has entered into definitive agreements with selected institutional investors to purchase approximately $60.8 million of its common stock in a registered direct offering. Under the terms of the offering, GTx will sell 3,799,600 shares of its common stock at a price of $16.00 per share, which represents a 4.7% discount to the closing price on December 12, 2006. GTx's net proceeds following payment of its expenses are expected to be approximately $57.4 million. The shares are being offered directly by GTx pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. GTx anticipates that the net proceeds from the offering will be used to fund clinical development and other research and development activities and for working capital and general corporate purposes. The closing of this offering is expected to occur on December 18, 2006, subject to satisfaction of customary closing conditions. Lazard Capital Markets LLC acted as the lead placement agent and Cowen and Company, LLC acted as co-placement agent for the offering. The shares of common stock may only be offered by means of a prospectus supplement and accompanying prospectus, a copy of which may be obtained, when available, from Lazard Capital Markets, LLC at 30 Rockefeller Plaza, 60th floor, New York, NY 10020. ____________ I really think they could have, should have, gone for more.